Researchers at Hokkaido University in Japan, in a collaboration with American scientists, may have identified neural crosstalk as the mechanism that drives widespread inflammation in inflammatory diseases, such as rheumatoid arthritis (RA), psoriasis and atherosclerosis.

The U.S. Food and Drug Administration approved Novartis’ Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis.

The U.S. Food and Drug Administration approved a supplemental Biologics License Application for Eli Lilly and Company’s Taltz (ixekizumab) injection 80 mg/mL for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation.

Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.

Novartis announced detailed results from the Phase III PREVENT trial, evaluating the efficacy and safety of Cosentyx (secukinumab) in patients with non-radiographic axial spondyloarthritis.

A little more than a week after announcing plans to acquire Ra Pharmaceutical for $2.1 billion, UCB’s psoriasis drug bimekizumab met all endpoints in the first of three Phase III studies.

Novartis’ Cosentyx hit the mark in treating patients with non-radiographic axial spondyloarthritis (nr-axSpA) in a Phase III trial.

Novartis announced positive new data from a Phase III trial evaluating the efficacy and safety of Cosentyx (secukinumab) in non-radiographic axial spondyloarthritis.

Eli Lilly announced results from the COAST-X Phase III study of Taltz in non-radiographic axial spondyloarthritis in patients who had no previous disease-modifying anti-rheumatic drug treatment.